ClinicalTrials.gg
CompletedNCT03961945Updated Oct 13, 2026

Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma

An interventional study of Sponge Capsule in Barrett Esophagus and Esophageal Adenocarcinoma, sponsored by Mayo Clinic. Completed at 8 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 13, 2026Now CompletedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,526
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Barrett Esophagus by Mayo Clinic — 6 open to participants now, 6 under way, none of them phase 3. Barrett Esophagus · Mayo Clinic.

Enrollment
Largest of 19
1,526 · median 60
Started
2021
the only one that year
No phase
13 of 40
3 open now
Registered
34th of 40
by date

Among the 40 studies in Barrett Esophagus by Mayo Clinic, this one has the largest enrollment of the 19 interventional ones that give a count, is the only one that started in 2021, is one of 13 with no phase, and was the 34th registered.

Barrett Esophagus

312 studies on the registry are indexed under Barrett Esophagus; 60 are open to participants now.

Browse Barrett Esophagus studies →

Open to participants now

6 of the 40 studies in Barrett Esophagus by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 44 Barrett Esophagus studies recruiting now, 31 (70%) set no upper age limit and 2 (5%) stop at 75 or younger; 4 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Barrett Esophagus by Mayo Clinic, or all of them as a file.
02

Study summary

This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux disease.

Read the detailed description

The sponge on a string (SOS) device will be safely administered by a non-physician such as a nurse. Novel discriminant methylated DNA markers will be assayed on esophageal cytology specimens obtained from the SOS device to enable detection in Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection.

03

Conditions studied

  • Barrett Esophagus
  • Esophageal Adenocarcinoma

Keywords

  • Barrett's Esophagus
  • Gastroesophageal Reflux
  • Reflux
  • Esophageal Cancer
  • Esophageal Adenocarcinoma
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria Aim1:

  • Male and female ages 50-85
  • Patients who have three or more risk factors for Barrett's Esophagus.
  • Gastroesophageal reflux disease defined by:

    • Diagnosis
    • Use of one of the following drugs >= 3 months over the last 5 years: omeprazole, esomeprazole, pantoprazole, rabeprazole, dexlansoprazole, lansoprazole, ranitidine, famotidine, cimetidine
    • prior endoscopic diagnosis of erosive esophagitis
  • (BMI) >= 30

Exclusion Criteria Aim1 and Aim 3:

  • Previous history of:

    • esophageal adenocarcinoma/cancer
    • esophageal squamous carcinoma
    • endoscopic ablation for Barrett's esophagus
    • esophageal squamous dysplasia
  • Current treatment with oral anticoagulation including Warfarin, Coumadin
  • History of cirrhosis
  • History of esophageal/gastric varices
  • History of Barrett's esophagus
  • Prior endoscopy in the last 5 years

Inclusion criteria Aim 2 and Aim 3:

  • Subjects with known or suspected BE (cases).

    • Patient between the ages 18 - 90.
    • Patients with a BE segment ≥ 1cm in maximal extent endoscopically or suspected BE in medical record.
    • Histology showing evidence of intestinal metaplasia with or without presence of dysplasia or suspected BE in medical record.
    • Undergoing clinically indicated endoscopy.
  • Subjects without known history of BE (controls).

    • Undergoing clinically indicated diagnostic endoscopy.

Exclusion criteria Aim 2:

  • Subjects with known BE.

    • Patients with prior history of ablation (photodynamic therapy, radiofrequency ablation, cryotherapy, argon plasma coagulation). Patients with history of endoscopic mucosal resection (EMR)/endoscopic submucosal dissection (ESD) alone will not be excluded.
    • Patients with history of esophageal resection for esophageal carcinoma.
  • For subjects with or without known evidence of BE (on history or review of medical records):

    • Pregnant or lactating females.
    • Patients who are unable to consent.
    • Patients with current history of uninvestigated dysphagia (this does not apply to the brushings/ only portion of the study).
    • History of eosinophilic esophagitis, achalasia.
    • Patients on oral anticoagulation including Coumadin, Warfarin (this does not apply to the brushings/biopsies only portion of the study).
    • Patients on antiplatelet agents including Clopidogrel, unless discontinued for three to five days prior to the sponge procedure.
    • Patients on oral thrombin inhibitors including Dabigatran and oral factor Xa inhibitors such as rivaroxaban, apixaban and edoxaban, unless discontinued for three to five days prior to the sponge procedure.
    • Patients with history of known esophageal or gastric varices or cirrhosis.
    • Patients with history of surgical esophageal resection for esophageal carcinoma.
    • Patients with congenital or acquired bleeding diatheses.
    • Patients with a history of esophageal squamous dysplasia.
    • Patient has known carcinoma of the foregut (pancreatic, bile duct, ampullary, stomach, or duodenum) within 5 years prior to study enrollment.
    • Patient has received chemotherapy class drugs or radiation to treat mediastinal or esophageal cancer.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,526 participants (actual)

Study arms

  • Other
    Screening Population

    Those that have gastroesophageal reflux or other risk factors for Barrett's Esophagus will be contacted and if agreeable undergo sponge capsule procedure and fill out questionnaires.

    Device: Sponge Capsule

  • Other
    Upper endoscopy - Barrett's Esophagus

    Those that have a diagnosis of Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.

    Device: Sponge Capsule

  • Other
    Upper endoscopy - No Barrett's Esophagus

    Those that have no known Barrett's Esophagus and are scheduled for an upper endoscopy will be approached and if agreeable undergo sponge capsule procedure as well as endoscopic biopsies and brushings of the esophagus.

    Device: Sponge Capsule

Interventions

  • DeviceSponge Capsule

    Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.

    Also known as: EsophaCap, Cytosponge

06

What researchers measure

Primary outcomes

  1. Aim 1 - Screening Population

    To measure the positive and negative predictive value of the sponge capsule Barrett's esophagus test in a screening population.

    Time frame: 5 years

  2. Aim 2 - Case/Control Population BE Detection

    Compare the sensitivity and specificity of a predetermined BE prediction algorithm for those with and without GERD and assess the influence of other covariates (age, sex, ever smoking, ethnicity and BMI) on this algorithm.

    Time frame: 5 years

  3. Aim 3 - Dysplasia Detection Sensitivity and Specificity

    Measure the sensitivity and specificity of a predetermined MDM panel assayed on SOS specimens from BE patients identified in Aims 1 and 2, for the detection of HGD /EAC, using surveillance histology as the criterion standard.

    Time frame: 5 years

Secondary outcomes

  1. Aim 1 - Screening Population Predictive Value

    Compare positive predictive value and negative predictive value of the sponge capsule Barrett's Esophagus test between those with and without chronic GERD.

    Time frame: 5 years

  2. Aim 1 - Screening Population Safety and Tolerability of sponge capsule procedure

    Safety and tolerability of the sponge capsule device in a screening population as measured by a Tolerability Questionnaire with sponge capsule procedure. Participants will rate their tolerability by rating questions using a scale of 0-10 (0 is none and 10 is severe or 0 is good and 10 is not good).

    Time frame: 5 years

  3. Aim 2 - Case/Control Population Sensitivity and Specificity

    Validate specificity and sensitivity cut offs of a BE prediction algorithm in an independent patient cohort

    Time frame: 5 years

  4. Aim 3 - Dysplasia Detection Rate of Missed Dysplasia

    Measure diagnostic uncertainty bias in the criterion standard, specifically, the rate of dysplasia missed by surveillance histology

    Time frame: 5 years

07

Study locations

8 sites
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Mayo Clinic Health Systems - Austin
    Austin, Minnesota 55912, United States
  • Mayo Clinic Health Systems - Mankato
    Mankato, Minnesota 56001, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Northwell Health
    New Hyde Park, New York 11040, United States
  • Baylor Scott & White Research Institute
    Dallas, Texas 75246, United States
  • Mayo Clinic Health System-Eau Claire
    Eau Claire, Wisconsin 54701, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Nov 2025, 52 months.

Of 65 non-industry interventional studies with no phase under Barrett Esophagus, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 108. This study's 52 months is close to that.

Counting every sponsor, half of 76 studies reached it within 45 months; a quarter within 23 and three quarters within 108.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jul 2030 → Nov 2025 and completion Jul 2030 → Nov 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 23, 2019
StartActual
Jul 1, 2021
Primary completionActual
Nov 25, 2025was Jul 2030
CompletionActual
Nov 25, 2025was Jul 2030
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 13, 2026
Sites
1 site removed
Show 1 removed
  • Mayo Clinic Health System-Franciscan Healthcare · La Crosse, United States
Oct 13, 2026
Primary completion
Jul 30, 2030→Nov 25, 2025 (actual)
Oct 13, 2026
Study completion
Jul 30, 2030→Nov 25, 2025 (actual)
Oct 13, 2026
Enrollment
1550 (estimated)→1526 (actual)
Oct 13, 2026
Documents
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Completed
    1 site removed
    Show 1 removed
    • Mayo Clinic Health System-Franciscan Healthcare · La Crosse, United States
    Primary completion Jul 30, 2030→Nov 25, 2025 (now actual)
    Study completion Jul 30, 2030→Nov 25, 2025 (now actual)
    Enrollment 1550 (estimated)→1526 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03961945
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
May 23, 2019
Start date
Jul 1, 2021
Primary completion
Nov 25, 2025
Completion
Nov 25, 2025
Last update
Oct 13, 2026

Study contacts

Prasad G. Iyer, M.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion